: iStockAnalyst.com Symbols Feed

ImmunoCellular (OTC: IMUC.OB) Notches Deal For New Cancer Stem Cell Vaccine Target

Wed, 02 Dec 2009 15:04:42 GMT

In an option agreement announced today with MD Anderson Medical Center, ImmunoCellular Therapeutics (OTC: IMUC.OB) has acquired the rights to novel peptides that elicit a T-cell immune response against validated cancer stem cell targets known as the Notch and Numb pathways.[More...]

A Busy Month For Immunogen (Part I)

Wed, 02 Dec 2009 09:55:00 GMT

The month of December has always been a busy period for biotech investors, due to two important events: The annual meeting of American Society of Hematology (ASH) and the San Antonio Breast Cancer Symposium (SABCS). Every year, these events produce clinical data that can sharply move biotech stocks in both directions. This year, Immunogen (IMGN) is about to get center stage attention at both events.[More...]

Invest In HealthCare!

Tue, 01 Dec 2009 16:52:08 GMT

In 3 of the past 4 market rebounds since 1982, equity gains slowed to a single digit pace in the 2nd year, after the initial rally. Now dividend stocks have extra appeal because they offer a tempting alternative to CDs which pay virtually no interest at all, and long term bonds which pay a little bit more but leave you at the mercy of inflation. Established value companies in stable industries have usually proven a better long-term investment. Before S&P cut Pfizer (PFE) ratings to 'AA' from 'AAA' on Oct 16, 2009, there were 5 companies with AAA credit ratings: Automated Data Processing (ADP), Johnson & Johnson (JNJ), ExxonMobil (XOM) and Microsoft (MSFT). In other words, 2 out of 5 were healthcare companies.[More...]

The Week In Review: CROs Consolidating

Mon, 23 Nov 2009 03:05:55 GMT

PPD, Inc. will acquire BioDuro, a preclinical CRO, as a follow-up to its purchase last month of Excel PharmaStudies, both of which are major transactions; we reflected on the huge difference between how China and the US go about creating “life science clusters”; China enrolled a record number of students in American universities during 2008-9; China Cord Blood listed on the NYSE and also completed a secondary offering; Advanced BioMedical signed an agreement in China to develop its bio-absorbable material in new applications;[More...]

GSK To Manufacture Flu Treatment Relenza In China

Fri, 20 Nov 2009 20:49:03 GMT

GlaxoSmithKline will begin manufacturing its treatment for flu, Relenza, in China to supply China’s domestic market. GSK received approval of the drug in September from the SFDA. Relenza, like Tamiflu from Roche, aims at reducing both the severity and the duration of flu symptoms, though some resistance to the drugs seems to be evident.[More...]

Lazard Puts Future In M&A with New CEO

Wed, 18 Nov 2009 01:02:35 GMT

In a signal of confidence for the future of mergers-and-acquisitions (M&A), Lazard Ltd. (NYSE: LAZ) appointed Kenneth Jacobs as its chairman and chief executive officer following the unexpected death of famed dealmaker Bruce Wasserstein.[More...]

Diversify Away With EFA!

Tue, 10 Nov 2009 21:55:58 GMT

Diversify Your Portfolio Outside the US Asset allocation is the most influential factor on investment outcome. There have been growing signs that the worst of the global crisis might have passed. While the US dollar may continue to weaken and the US loses significance in the global landscape, an allocation to other developed markets is deemed necessary. After all, 76% of global GDP is outside the US.[More...]

Big Pharma And Biotech - Industry Outlook

Mon, 09 Nov 2009 21:58:02 GMT

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.[More...]

Dr. Reddy's Laboratories (RDY) Impressive On Both Fundamental And Technical Basis

Mon, 09 Nov 2009 17:00:18 GMT

While I've traded Dr. Reddy's Laboratories (RDY) in the past, I have not touched it in the past few years; however as we await for the new Market Vectors Indian Small Cap fund to launch I was poking my nose around Indian stocks this weekend since the Indian market has corrected quite a bit (and rebounded from oversold levels last week). So this name came back onto my radar in the limited universe of Indian ADRs. (full list of Indian stocks available at TickerSpy)[More...]

Closing: Late Charge Allows Stocks To End Volatile Trade On Upbeat Note

Mon, 02 Nov 2009 20:35:00 GMT

A late-day charge landed all major averages in positive territory. The DJIA advances 0.7%. The S&P 500 is up 0.6%. The Nasdaq Composite is up 0.2%.[More...]

Evening Standard, London, market report column

Thu, 03 Dec 2009 18:48:00 GMT

Dec. 3--Commodity stocks should keep rising next year, but the best is behind the financials.
That's the opinion of Goldman Sachs, whose strategy suggestions for 2010 were being circulated in the City today.
Shares in London rose, with the FTSE putting on 30.71 points to 5358.10 as the banks bounced back from yesterday's losses.

[More...]

Seasonal flu vaccine supplies spur worries

Tue, 24 Nov 2009 15:20:00 GMT

Seasonal flu vaccine supplies spur worries[More...]

FDA approves additional H1N1 vaccine

Mon, 16 Nov 2009 19:44:00 GMT

FDA approves additional H1N1 vaccine[More...]

Daily Mail, London, market report column

Fri, 13 Nov 2009 18:47:00 GMT

Nov. 13--Lansdowne Partners, one of London's largest and shrewdest hedge funds, began the year making a mint out of betting on the hefty fall in the Barclays' share price.
Cattle genetics group Genus, famous for its Friesian bull Picston Shottle and in which Lansdowne holds 12.4pc, fell 70p to 570p.
The company, which sells semen from high yield strains of cows and pigs to farmers, warned that the US market has continued to deteriorate as dairy farmers trade down and pig farmers put off investing in new animals.

[More...]

Drug industry presses FDA to allow more online ads

Wed, 11 Nov 2009 19:52:00 GMT

WASHINGTON - As federal regulators take their first tentative steps toward policing the wild west of medical information online, pharmaceutical companies are pressing their case to market drugs via Google, Twitter and other Web sites.
The Food and Drug Administration will convene a two-day meeting beginning Thursday to hear the drug industry's position on Internet marketing.
The agency has agreed to consider developing rules for online advertising after companies complained that the current guidelines for traditional media - which require a detailed list of possible side effects - have left them hamstrung on the Web.

[More...]

Targacept has profit in quarter: Large milestone payment by AstraZeneca credited for first profit in almost three years

Fri, 06 Nov 2009 11:46:00 GMT

Nov. 6--Targacept Inc. posted its first quarterly profit in nearly three years yesterday, bolstered in large part by a $10 million milestone payment by AstraZeneca PLC.
Targacept, based in Piedmont Triad Research Park in Winston-Salem, is developing drugs based on nicotine research to treat diseases of the central nervous system.
The payment was the result of Targacept's research in adult attention deficit/hyperactivity disorder involving its AZD3480 drug compound, also known as TC-1734.

[More...]

Auditor: Canada disaster planning is poor

Wed, 04 Nov 2009 15:07:00 GMT

Auditor: Canada disaster planning is poor[More...]

Vaccine-short Canada exporting 'surplus'

Wed, 04 Nov 2009 12:06:00 GMT

Vaccine-short Canada exporting 'surplus'[More...]

Largest malaria vaccine trial under way

Tue, 03 Nov 2009 15:03:00 GMT

Largest malaria vaccine trial under way[More...]

Canada's H1N1 flu vaccine running short

Fri, 30 Oct 2009 12:24:00 GMT

Canada's H1N1 flu vaccine running short[More...]

Procter &Amp; Gamble Co. Up 13% Since Added to Galtstock Long Portfolio

Fri, 23 Oct 2009 21:07:00 GMT

Subscribers to galtstock.com "Long-Term Portfolio" service (membership) invest in solid long-term holdings.
Other stocks in our portfolio are Procter & Gamble (NYSE: PG), Coca-Cola (NYSE: KO), GlaxoSmithKline (NYSE: GSK), and McDonald's Corp. (NYSE: MCD).
To sign up for Galt's Long-Term Portfolio service, please visit the website at http://www.galtstock.com/Long-Term-Portfolio.html with secure check out.

[More...]

Pronova BioPharma Receives 2009 Frost &Amp; Sullivan Award for Excellence in Financial &Amp; Risk Management

Tue, 08 Sep 2009 15:48:00 GMT

8 September 2009, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or "the company") today announces that it has been awarded the 2009 Frost & Sullivan Excellence in Financial & Risk Management Award in the Global Heart Health Ingredients market for its lead product Omacor(R)/LovazaTM, the first and only EU- and FDA-approved omega-3 derived prescription drug.
The Frost & Sullivan Excellence in Financial & Risk Management Awards are presented annually to companies that demonstrate outstanding management of current market conditions, besides preparing for the future, above others within their respective industries.
This award recognises Pronova BioPharma's excellent product quality and favourable customer opinions, continued strong customer demand for Omacor/Lovaza, innovation supporting next generation omega-3 derived products (through ongoing collaborations in indications such as heart failure, atrial fibrillation and cardiac disease in type II diabetic patients) and sound operational and financial risk management practices.

[More...]

Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma

Tue, 08 Sep 2009 11:46:00 GMT

LONDON, Sept. 8 /PRNewswire/ -- The 2009 Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award is presented to Pronova BioPharma ASA.
Pronova BioPharma has demonstrated excellence in financial management.
Pronova BioPharma's return on assets (ROA) improved from 16.8 per cent in 2007 to 34.5 per cent in 2008.

[More...]

85% Profitable Trades Keep Galtstock.Com Subscribers Very Happy

Thu, 27 Aug 2009 15:09:00 GMT

The market is chopping up and down with lack of conviction, there are still great trading opportunities every week.
Subscribers to galtstock.com "SwingTrader" service (Membership) recently closed a trade in United Airlines for a 10% gain in 1 day.
Other closed trades this month were U.S. Oil Fund for 11.7% gain and FreePort-McMoran for a 10.1% profit.

[More...]

Tennis Legend John McEnroe Tells Men to 'Get Serious' About Prostate Cancer

Thu, 27 Aug 2009 13:28:00 GMT

Seven-time grand slam winner John McEnroe, whose father was diagnosed with prostate cancer in 2006, is providing his voice and image to a new campaign that promotes recently updated prostate-cancer screening guidelines.[More...]

GSK Advisory: Warehouse Theft

Mon, 24 Aug 2009 20:26:00 GMT

GlaxoSmithKline is advising that two lots of Advair Diskus medication were stolen on August 2 from the company's distribution facility near Richmond, Virginia. Medicine in the stolen cartons could represent a health risk because it has been removed from the legitimate supply chain and the storage conditions under which the stolen products were held are unknown. Inhalers from these lots should not be dispensed, sold, or used.[More...]

Pharmacoeconomic Analysis of Reported Use of ENTEREG(R) (alvimopan) Published in American Journal of Health-System Pharmacy

Thu, 20 Aug 2009 20:33:00 GMT

EXTON, PA and PHILADELPHIA, PA -- -- 08/20/09 -- Adolor Corporation and GlaxoSmithKline today announced that an economic analysis of Phase 3 clinical trial data reported that the use of ENTEREG after bowel resection surgery decreased the amount of time patients spent in the hospital by one day, resulting in lower estimated hospital costs compared with placebo. The results, published in the American Journal of Health-System Pharmacy, were based on a post-hoc pharmacoeconomic analysis of pooled data consisting of 1,409 patients who participated in four randomized, double-blind, placebo-controlled, Phase 3 efficacy studies of ENTEREG conducted in North America.[More...]

Video: FDA Approves GSK's Hib Vaccine, Hiberix(R)

Thu, 20 Aug 2009 00:09:00 GMT

In response to a U.S. shortage of a vaccine to protect infants from Haemophilus influenzae type b , GlaxoSmithKline has received accelerated approval from the FDA for Hiberix) [Haemophilus b Conjugate Vaccine ] as a booster dose in children 15 months through four years of age.Hib is an often severe and potentially deadly bacterial infection that can cause meningitis.[More...]

Pharmerging Versus Mature Pharmaceutical Markets: Where Is Pharma Going? Where Is Pharma Growing? -- an Industrial Info News Alert

Wed, 12 Aug 2009 11:52:00 GMT

Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- One of the latest trendy phrases zipping around the Pharmaceutical Industry is "pharmerging markets."
The pharmerging areas are poised to receive the next major influx of capital activity from all of the Pharmaceutical Industry majors, e.g. Pfizer Incorporated (NYSE:PFE), GlaxoSmithKline plc (NYSE:GSK), Merck & Company Incorporated (NYSE:MRK), albeit with a definite risk of losing both intellectual and physical property.
For details, view the entire article by subscribing to Industrial Info's Premium Industry News at http://www.industrialinfo.com/showNews.jsp?newsitemID=149279, or browse other breaking industrial news stories at www.industrialinfo.com.

[More...]

StockPreacher.com Issues Trading Outlook for ViroPharma Inc.

Tue, 04 Aug 2009 10:46:00 GMT

StockPreacher.com announces an investment report featuring biopharmaceutical company ViroPharma Inc. . The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.[More...]